Sumitomo Pharma to consolidate key U.S. assets

Sumitomo Pharma Co., Ltd. (TSE:4506) announced today a strategic decision to assign substantially all assets, including patent rights, for its key U.S. products—ORGOVYX®, GEMTESA®, and MYFEMBREE®—from its subsidiaries Sumitomo Pharma Switzerland GmbH (SMPS) and Urovant Sciences GmbH (USG). The move aims to streamline the management and operation of the U.S. business, making Sumitomo Pharma America, Inc. (SMPA) and SMPS its direct subsidiaries. The total assignment price is estimated at USD 1.8 billion and will be settled through the offset of existing loans from Sumitomo Pharma to SMPS. The effective date of the assignment is set for August 1, 2025. The Board of Directors approved the resolution on June 26, 2025. Sumitomo Pharma anticipates that this reorganization will have a minor impact on the company's consolidated financial results.